| [1] |
陈万青, 郑荣寿, 曾红梅, 等. 2011年中国恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2012, 24(1): 1-10.
|
| [2] |
叶定伟. 前列腺癌的流行病学和中国的发病趋势[J]. 中华外科杂志, 2006, 44(6): 362-364.
|
| [3] |
董隽. 激素难治性前列腺癌对多西他赛耐药机制的研究进展[J]. 中华泌尿外科学杂志, 2011, 32(2): 138-140.
|
| [4] |
Lassi K, Dawson NA. Emerging the rapiesin castrate-resistant prostate cancer[J]. Curr Opin Oncol, 2009, 21(3): 260-265.
|
| [5] |
Lam JS, Leppert JT, Vemulapalli SN, et al. Secondary hormonal therapy for advanced prostate cancer[J].Urol, 2006, 175(1): 27-34.
|
| [6] |
那彦群, 叶章群, 孙颖浩, 等. 2014版中国泌尿外科疾病诊断治疗指南[M]. 人民卫生出版社, 2013, 80.
|
| [7] |
Tannock IF,Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points[J]. J Clin Oncol, 1996, 14(6): 1756-1764.
|
| [8] |
Tannock IF, de Wit R, Berry W R, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer[J]. N Engl J Med, 2004, 351 (15): 1502-1512．
|
| [9] |
De Bono JS, Oudard S, Ozguroglu M, et a1. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial[J]. Lancet, 2010, 376(9747): 1147-1154.
|
| [10] |
陈彼得, 俞世成, 李恭会. 多西他赛治疗失败后的去势抵抗性前列腺癌及其骨转移治疗进展[J]. 浙江大学学报（医学版），2014, 43(1): 115-118,封3.
|
| [11] |
Omlin A, Pezaro C, Gillessen Sommer S. Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy[J]. Ther Adv Urol, 2014, 6(1): 3-14.
|
| [12] |
Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer[J]. J Clin Oncol, 2009, 27(23): 3742-3748.
|
| [13] |
De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer[J]. N Engl J Med, 2011, 364(21): 1995-2005.
|
| [14] |
Tran C, Ouk S, Cleegg NJ, et al. Development of a second-generation antiandrogen for treatment of ad-vanced prostate cancer[J]. Science, 2009, 324(5928): 787-790.
|
| [15] |
Ferlay J,Shin H R,Bray F, et al.Estimates of world-wide burden of cancer in 2008: GLOB-OCAN 2008[J].Int J Cancer, 2010, 127(12): 2893-2917.
|
| [16] |
Beer T M, Tombal B. Ezalutamide in metastatic pros-tate cancer before chemotherapy[J]. N Engl J Med, 2014, 371(18): 1755-1756.
|
| [17] |
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for Castration-Resistant prostate cancer[J]. N Engl J Med, 2010, 363(5): 411-422.
|
| [18] |
Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer[J]. Cancer, 2009, 115(16): 3670-3679.
|
| [19] |
Simondsen K, Kolesar J. New treatment options for castration-resistant prostate cancer[J]. Am J Health Syst Pharm, 2013, 70(10): 856-865.
|
| [20] |
许标波, 贺毅憬, 王韦力, 等. 肿瘤免疫检查点抑制剂临床治疗的研究进展[J]. 中国临床药理学与治疗学, 2016, 21(2): 218-224.
|
| [21] |
Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase3 trial[J]. Lancet Oncol, 2014, 15(7): 700-712.
|
| [22] |
Lee RJ. Smith MR. Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer[J]. Cancer J, 2013, 19(1): 90-98.
|
| [23] |
Lee RJ, Saylor PJ, Michaelson MD, et al. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases[J]. Clin Cancer Res, 2013, 19(11): 3088-3094.
|
| [24] |
Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial[J]. J Clin Oncol, 2013, 31(4): 412-419.
|
| [25] |
田俊波, 董自强, 曾文, 等. 分子靶向治疗在前列腺癌中的研究进展[J]. 现代生物医学进展, 2015, 15(10): 1984-1986.
|
| [26] |
Nilsson S, Franzén L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study[J]. Lancet Oncol, 2007, 8(7): 587-594.
|
| [27] |
温耀安, 王沈凡, 宋先璐, 等. 二氯化镭223治疗伴骨转移前列腺癌的药理及临床评价[J]. 中华泌尿外科学杂志, 2016, 37(11):878-880.
|
| [28] |
Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA Guideline[J]. J Urol, 2013, 190(2):429-438.
|
| [29] |
Coogan CL, McKiel CF. Percutaneous cryoablation of the prostate: preliminary results after 95 procedures[J]. J Urol, 1995, 154(5): 1813-1817.
|
| [30] |
中华医学会泌尿外科学分会, 中国前列腺癌联盟. 转移性前列腺癌化疗中国专家共识(2017版)[J]. 中华泌尿外科学杂志, 2017, 38(3): 161-165.
|
| [31] |
陈征, 邵春奎, 高新. Gleason评分研究进展及评估前列腺癌预后的重要性[J/CD]. 中华腔镜泌尿外科杂志(电子版), 2016, 10(6): 367-372.
|
| [32] |
Lubaroff DM. Prostate cancer vaccines in clinical trials[J]. Expert Rev Vaccines, 2012, 11(7): 857-868．
|